Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 33, 08 March 2024
Open
Access | Article
Exploration and determination of lung cancer targets using multi-omics approaches
* Author to whom correspondence should be addressed.
Abstract
Multi-omics analysis is a relatively new approach which sets of data are combined for analysis. It integrates the genomic, epigenomic, transcriptomic, proteomic, and metabolomic data from diseased individuals and is capable of comparing the different changes in levels of each identified molecules with the assist of charts and graphs by information technologies, ultimately proposing potential biomarkers and correlations that are possible targets for cancer drugs. Lung cancer, nowadays is the most common cancer being diagnosed worldwide. Thus, lung cancer, amongst the remaining cancer, should not be overlooked. The pathogenesis and treatment of lung cancer is an urgent problem in the medical field that needs to be researched thoroughly. By integrating this new approach to the most common cancer, we try to find more possibilities for targeted drug development. We analyzed the data from the existing database to find out whether the control group and the disease group were up-regulated or down-regulated to analyze some targets, contributing to the development of targeted drugs.
Keywords
Lung adenocarcinoma, Multi-omics, Drug targets
References
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209-249. https://doi.org/10.3322/caac.21660
3. Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, Wei W, Li G, Cheng X, Xue L, Li Y, Chen H, Wei S, Sun R, Cui H, Meng Y, Liu M, Li Y, Feng R, Yu X, Zhu R, Wu Y, Li L, Yang B, Ma Y, Wang J, Zhu W, Deng D, Xi Y, Wang F, Li H, Guo S, Zhuang X, Wang X, Jiao Y, Cui Y, Zhan. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell. 2023 Jan 9;41(1):181-195.e9. doi: 10.1016/j.ccel2022.12.004. Epub 2022 Dec 29. PMID: 36584672
4. Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563-1579. doi: 10.1158/1055-9965.EPI-19-0221. PMID: 31575553; PMCID: PMC6777859.
5. Asada, K., Kobayashi, K., Joutard, S., Tubaki, M., Takahashi, S., Takasawa, K., Komatsu, M., Kaneko, S., Sese, J., & Hamamoto, R. (2020). Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer. Biomolecules, 10(4). https://doi.org/10.3390/biom1004052
6. Luan, M., Song, F., Qu, S., Meng, X., Ji, J., Duan, Y., Sun, C., Si, H., & Zhai, H. (2020). Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets. Oncol Lett, 20(4), 58. https://doi.org/10.3892/ol.2020.11919
7. Chen, M., Li, S., Liang, Y., Zhang, Y., Luo, D., & Wang, W. (2021). Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate OncogenCorrelates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer. Front Oncol, 11, 656509. https://doi.org/10.3389/fonc.2021.656509
8. Dong, X., Leng, Y., Tian, T., Hu, Q., Chen, S., Liu, Y., & Shen, L. (2023). GALNT2, an O-glycosylating enzyme, is a critical regulator of radioresistance of non-small cell lung cancer: evidence from an integrated multi-omics analysis. Cell Biol Toxicol. https://doi.org/10.1007/s10565-023-09825-6
9. Zhang L, Parvin R, Chen M, Hu D, Fan Q, Ye F. High-throughput microfluidic droplets in biomolecular analytical system: A review. Biosens Bioelectron. 2023 May 15;228:115213. doi: 10.1016/j.bios.2023.115213. Epub 2023 Mar 8. PMID: 36906989.
10. Daftuar, L., Zhu, Y., Jacq, X., & Prives, C. (2013). Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One, 8(7), e68667. https://doi.org/10.1371/journal.pone.0068667
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-323-4
- ISBN (Online)
- 978-1-83558-324-1
- Published Date
- 08 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/33/20240767
- Copyright
- 08 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited